NCCN is offering a series of twelve multidisciplinary case-based webinars on a variety of topics, including ALL, breast cancer, cervical cancer, gastric cancer, head and neck cancer, lung cancer, lymphoma, colorectal cancer, malanoma, prostate cancer, and diffuse large B-cell lymphoma in young adults. Each webinar will be facilitated by two faculty members providing multidisciplinary perspectives. A different topic will be presented each month for twelve months (June 2015 until June 2016).

The NCCN Guidelines are a set of step-by step evidence-based, consensus-driven recommendations that ensure that patients receive preventive, diagnostic treatment, and care that is most likely to lead to optimal outcomes. The NCCN recommendations are applicable to about 95% of patients. Clinicians need to consider the current clinical status of the patient, including general health, disease specifics, concomitant conditions, current and previous therapies, and the patients how to best apply appropriate standard of care including identifying circumstances where appropriate management requires adapting the NCCN Guidelines to the needs of the individual. This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the NCCN Guidelines might be best applied.

Intended Audience
These educational programs are designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Accreditation
These activities are approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided for all sessions. Complete accreditation information is provided before each individual educational activity.

Fee Information
There are no fees for these activities.

Supporters
These activities are supported by educational grants from BTG; Bristol-Myers Squibb; Celgene Corporation; Genomic Health, Inc.; Lilly; Merck; Novartis Oncology; Prometheus Laboratories, Inc.; and Spectrum Pharmaceuticals, Inc.  These activities are supported by a grant from AstraZeneca.  These activities are supported by an independent educational grant from Boehinger Ingelheim Pharmaceuticals, Inc.